Holen Sie sich die Stockscreener-App
1.15
4.55%
0.05
Vorhandelsmarkt:
1.17
0.02
+1.74%
Schlusskurs vom Vortag:
$1.10
Offen:
$1.13
24-Stunden-Volumen:
320.72K
Relative Volume:
0.06
Marktkapitalisierung:
$7.19M
Einnahmen:
$513.90K
Nettoeinkommen (Verlust:
$-48.50M
KGV:
-0.0411
EPS:
-28.0101
Netto-Cashflow:
$-28.99M
1W Leistung:
-22.82%
1M Leistung:
-52.87%
6M Leistung:
-64.22%
1J Leistung:
-87.42%
1-Tages-Spanne:
$1.08
$1.16
1-Wochen-Bereich:
$0.9396
$1.57
52-Wochen-Spanne:
$0.9396
$13.54
Co Diagnostics Inc Stock (CODX) Company Profile
Firmenname
Co Diagnostics Inc
Sektor
Branche
Telefon
(801) 438-1036
Adresse
2401 S FOOTHILL DRIVE, SALT LAKE CITY
Compare CODX vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CODX
Co Diagnostics Inc
|
1.15 | 6.88M | 513.90K | -48.50M | -28.99M | -28.01 |
ABT
Abbott Laboratories
|
114.14 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
327.70 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.30 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.37 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.83 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Co Diagnostics Inc Stock (CODX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-08-12 | Herabstufung | Sidoti | Buy → Neutral |
| 2021-12-29 | Eingeleitet | Sidoti | Buy |
| 2021-03-29 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-05-20 | Hochstufung | Maxim Group | Hold → Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
Co Diagnostics Inc Aktie (CODX) Neueste Nachrichten
CODX Forecast — Price Target — Prediction for 2027 - TradingView
ARMISTICE CAPITAL, LLC Buys Co-Diagnostics Inc (CODX) -- Shares Look 33% Undervalued on GF Value - GuruFocus
Co-Dx (CODX) Q2 2026 Earnings Call Transcript - The Globe and Mail
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet - Stocktwits
Co-diagnostics Company Profile & Introduction - Moomoo
Co-Diagnostics (CODX) Snapshot: Ends Up by 4.37% at $1.31 in the Current Update; Chart View - Vinanet
Co-Diagnostics Inc (CODX) Stock News Today - TradingKey
Co-Diagnostics seeks FDA clearance for new PCR Flu A/B & RSV test, prepping for U.S. launch. - Pluang
Co-Diagnostics joins Utah roundtable on AI and medical devices - Stock Titan
Why Did CODX Stock Nearly Double In Value Today? - Stocktwits
Maxim Group Upgrades Co-Diagnostics to Buy From Hold, $4 Price Target - marketscreener.com
Company-diagnostics Stock Price Forecast. Should You Buy CODX? - StockInvest.us
Armistice Capital discloses 9.99% Co-Diagnostics (CODX) holding via Master Fund - Stock Titan
Co-diagnostics | SCHEDULE 13G: Others - Moomoo
Co-Diagnostics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Co-diagnostics(CODX) Stock Options Chain | Quotes & News - Moomoo
CODX|Co-Diagnostics Inc|Price:1.460|Chg%:-0.020 - TradingKey
Co-Diagnostics (CODX) Earnings Call Q2 2026: FDA-Antrag schreitet voran, während Barmittel sinken - TradingKey
Co-Diagnostics (CODX) Q2 2026 Earnings Call: FDA Filing Advances as Cash Falls - TradingKey
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FD - GuruFocus
Is Co-Diagnostics Inc (CODX) Undervalued Despite Q2 Earnings Mis - GuruFocus
Co-Diagnostics Q2 Results: Net loss narrows to $6.3 million - scanx.trade
Co-Diagnostics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Earnings call transcript: Co-Diagnostics narrows loss in Q2 2026 but revenue stays thin - Investing.com
Co-Diagnostics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings - Quiver Quantitative
Q2 2026 Co-Diagnostics Inc Earnings Call Transcript - GuruFocus
Co-Diagnostics Q2 2026 Earnings: Losses Narrow as Revenue Stays Near $0.17 Million - TradingKey
Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity - Stock Titan
Co-Diagnostics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Co-Diagnostics Q2 revenue rises slightly amid international expansion - TradingView
Co-Diagnostics, Inc. (CODX) Latest Stock News & Headlines - Yahoo Finance
Press Release: Co-Diagnostics Reports Second Quarter 2026 Financial Results - 富途牛牛
Co-Diagnostics Inc (CODX) (Q2 2026) Earnings Call Highlights: FDA Submission Milestone and ... By GuruFocus - Investing.com Canada
CODX Q2'26 Earnings: EPS estimate is (3.00) USD - TradingView
Co-Diagnostics Inc expected to post a loss of $3.00 a shareEarnings Preview - TradingView
Co-Diagnostics (NASDAQ: CODX) sees Jane Street disclose 1.7% equity stake - Stock Titan
Co-diagnostics | SCHEDULE 13G/A: Others - Moomoo
Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance - respiratory-therapy.com
Co-Diagnostics Inc (CODX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CODX Stock Price, Quote & Chart - ChartMill
Co-Diagnostics submits FDA 510(k) for respiratory test By Investing.com - Investing.com South Africa
CODX Looks 28.1% Undervalued on GF Value™ Amid Challenging Finan - GuruFocus
Co-Diagnostics submits FDA application for dece... - Pluang
Co-Diagnostics submits FDA 510(k) for respiratory test - Investing.com
Co-Diagnostics Submits FDA 510(k) Premarket Notification for Upper Respiratory Point-of-Care Test - PR Newswire
CODX Q2'26 Earnings: revenue estimate is 132.58K USD - TradingView
Weekly Recap: Co-Diagnostics, Inc. Q2 results date and Bundibugyo test - TradingView
Co-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review - The Clinical Trial Vanguard
Why Is Co-Diagnostics (NASDAQ:CODX) In Focus After Its Latest Molecular Diagnostics Update? - Kalkine Media
Co-Diagnostics holders exercise 1,702,362 warrants at USD 1.57 per share in inducement deal - Bitget
Finanzdaten der Co Diagnostics Inc-Aktie (CODX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.76%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):